Method of testing anticancer agent-sensitivity of tumor cells

Details Method of testing anticancer agent-sensitivity of tumor cells Method of testing anticancer agent-sensitivity of tumor cells

2001-11-26

2008-11-04

Fetterolf, Brandon J (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

Reexamination Certificate

active

07445892

ABSTRACT:
Susceptibility of a tumor cell to an anticancer agent is tested by measuring an expression level or levels of a gene or genes selected from the group consisting of the genes listed in Tables 3 and 4 in a tumor cell collected from a cancer patient treated with an anticancer agent (E7070 and related compounds thereof), or causing the anticancer agent to act on a tumor cell collected from a cancer patient and measuring an expression level or levels of a gene or genes selected from the group consisting of the genes listed in Tables 3 and 4 in the tumor cell, and determining that the tumor cell is susceptible to the anticancer agent when the expression level or levels of the gene or genes listed in Table 3 increase, or the expression level or levels of the gene or genes listed in Table 4 decrease.

REFERENCES:
patent: WO 95/07276 (1995-03-01), None
patent: WO0055320 (2000-09-01), None
patent: WO 2006/036025 (2006-04-01), None
Staunton et al. (PNAS 2001; 98: 10787-10792).
Perou et al. (PNAS 1999; 96: 9212-9217).
Alizadeh et al. (Nature 2000; 403: 503-511).
Yokoi et al. (Molecular Cancer Therapeutics 2002; 1: 275-286).
Owa et al. (Bioorg. Med. Chem. Lett. 2000; 10: 1223-1226).
Stanislas et al. (Biochemical and Biophysical Research Communications 1998; 157: 1309-1315).
Kudoh, et al., “Monitoring the Expression Profiles of Doxorubicin-Induced and Doxorubicin-Resistant Cancer Cells by cDNA Microarry”,Cancer Research, 60: 4161-4166, 2000.
Rhee, et al., “Characterization of Cellular Pathways Involved in Glioblastomas Response to Chemotherapeutic Agent 1, 3-Bis(2-Chloroethyl)-1-Nitrosourea (BCNU) by Gene Expression Profiling”,Oncology Reports, 6: 393-401, 1999.
Owa, et al. “Discovery of Novel Antitumor Sulfonamides Targeting G1 Phase of the Cell Cycle,”Journal of Medical Chemistry, vol. 42, No. 19, pp. 3789-3799, 1999.
Owa, et al. “A Focused Compound Library of NovelN-(7-Indolyl)benzenesulfonamides for the Discovery of Potent Cell Cycle Inhibitors,”Bioorganic&Medicinal Chemistry Letters, vol. 10, No. 11, pp. 1223-1226, 2000.
Ozawa, et al. “E7070, A Novel Sulphonamide Agent with Potent Antitumor Activity in Vitro and In Vivo,”European Journal of Cancer, vol. 37, No. 17, pp. 2275-2282, 2001.
Owa, et al., “Microarry-based Expression Profiling Of Sulfonamide Anti-tumor Agents,”Proceedings of the American Association for Cancer Research Annual Meeting, 42: 371, 2001.
Watanabe, et al., “A Novel Anti-tumor Agent ER-35744, Targeting G1 Phase. III: Studies Of Mechanism Of Action,”Proceedings of the American Association for Cancer Research Annual Meeting, 37: 391, 1996.
Wu, et al., “Multidrug-Resistant Phenotype Of Disease-oriented Panels Of Human Tumor Cell Lines Used For Anti-cancer Drug Screening,”Cancer Research, 52: 3029-3034, 1992.
Supplementary European Search Report EP 01997200.9—2405 PCT/JP0110282, Dated Jan. 27, 2006, 2 pgs.
Scherf, et al.,Nature Genetics, 24(3): 236-244, Mar. 2000.
Zimmermann, et al.,Oncogene, 19(25): 2913-2920, Jun. 8, 2000.

Affiliated with

Also associated with

Rating

Method of testing anticancer agent-sensitivity of tumor cells does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of testing anticancer agent-sensitivity of tumor cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of testing anticancer agent-sensitivity of tumor cells will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4024488